Law Offices of Frank R. Cruz Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action
Law Offices of Frank R. Cruz Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action
Share
IF YOU SUFFERED A LOSS ON YOUR BIOHAVEN LTD. (BHVN) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.
You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.
What Happened?
On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint.
On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors.
Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]'
On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025.
Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025.
On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025.
Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.'
On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you purchased Biohaven securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:
Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
What To Expect From Philip Morris's (PM) Q2 Earnings
Tobacco company Philip Morris International (NYSE:PM) will be reporting results this Tuesday before market hours. Here's what to expect. Philip Morris beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $9.30 billion, up 5.8% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EBITDA estimates and a decent beat of analysts' gross margin estimates. Is Philip Morris a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Philip Morris's revenue to grow 8.6% year on year to $10.28 billion, improving from the 5.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.86 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Philip Morris has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 2.1% on average. Looking at Philip Morris's peers in the consumer staples segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Constellation Brands's revenues decreased 5.5% year on year, missing analysts' expectations by 1.5%, and McCormick reported flat revenue, in line with consensus estimates. Constellation Brands traded up 4.5% following the results while McCormick was also up 3.6%. Read our full analysis of Constellation Brands's results here and McCormick's results here. Investors in the consumer staples segment have had steady hands going into earnings, with share prices up 1.3% on average over the last month. Philip Morris is down 3.1% during the same time and is heading into earnings with an average analyst price target of $184.32 (compared to the current share price of $179.24). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
RTX (RTX) To Report Earnings Tomorrow: Here Is What To Expect
Aerospace and defense company Raytheon (NYSE:RTX) will be reporting results this Tuesday before market open. Here's what to look for. RTX beat analysts' revenue expectations by 1.7% last quarter, reporting revenues of $20.31 billion, up 5.2% year on year. It was a strong quarter for the company, with a solid beat of analysts' EBITDA estimates and an impressive beat of analysts' adjusted operating income estimates. Is RTX a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting RTX's revenue to grow 4.4% year on year to $20.65 billion, slowing from the 8.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.43 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. RTX has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 3.3% on average. Looking at RTX's peers in the aerospace and defense segment, some have already reported their Q2 results, giving us a hint as to what we can expect. AAR delivered year-on-year revenue growth of 14.9%, beating analysts' expectations by 8.6%, and Byrna reported revenues up 40.6%, in line with consensus estimates. AAR traded up 13.4% following the results while Byrna was down 28.8%. Read our full analysis of AAR's results here and Byrna's results here. There has been positive sentiment among investors in the aerospace and defense segment, with share prices up 6.5% on average over the last month. RTX is up 4.1% during the same time and is heading into earnings with an average analyst price target of $150.29 (compared to the current share price of $151.80). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
25 minutes ago
- Newsweek
FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments. The agency announced the action on Friday, citing serious safety concerns and "unreasonable and significant risk" to study participants. The FDA also revoked the company's platform technology designation and requested Sarepta voluntarily halt shipments of its approved drug Elevidys, which the company refused to do. Newsweek reached out to Sarepta Therapeutics via email on Sunday after normal business hours for comment. Why It Matters This regulatory intervention represents a significant safety measure in the gene therapy field, affecting both ongoing clinical trials and an already approved treatment for Duchenne muscular dystrophy. The decision could impact treatment options for families dealing with these devastating muscle-wasting diseases. Duchenne muscular dystrophy is a rare and serious genetic condition that worsens over time, leading to weakness and wasting away of the body's muscles. What To Know The three deaths resulted from acute liver failure in patients treated with either Elevidys or investigational therapies using the same AAVrh74 viral vector technology. One fatality occurred during a clinical trial for limb girdle muscular dystrophy treatment. Elevidys is an adeno-associated virus vector-based gene therapy designed to deliver a gene that leads to production of a shortened protein that contains selected domains of the dystrophin protein present in normal muscle cells. The disease occurs due to a defective gene that results in abnormalities in, or absence of, dystrophin, a protein that helps keep the body's muscle cells intact. The drug received traditional approval for ambulatory DMD patients aged 4 and older on June 20, 2024, while maintaining accelerated approval for non-ambulatory patients since June 22, 2023. Under accelerated approval, companies must conduct confirmatory studies to verify clinical benefit. Given the new safety concerns, the FDA has notified Sarepta that the drug's indication should be restricted to ambulatory patients only. The FDA revoked the platform technology designation for Sarepta's AAVrh74 Platform Technology because the preliminary evidence is insufficient to demonstrate that the technology has the potential to be incorporated in multiple drugs without adverse safety effects. What People Are Saying FDA Commissioner Marty Makary, M.D., M.P.H.: "Today, we've shown that this FDA takes swift action when patient safety is at risk. We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges." Dr. Vinay Prasad, Director of FDA's Center for Biologics Evaluation and Research: "Protecting patient safety is our highest priority, and the FDA will not allow products whose harms are greater than benefits. The FDA will halt any clinical trial of an investigational product if clinical trial participants would be exposed to an unreasonable and significant risk of illness or injury." FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. AP Photo/Jose Luis Magana, File What Happens Next The FDA will continue investigating the risk of acute liver failure and other serious outcomes following gene therapies using Sarepta's AAVrh74 platform technology. The agency has committed to taking additional regulatory actions as needed to protect patients. For current Elevidys patients, the FDA is focusing its safety investigation on ambulatory patients while restricting the drug's use in non-ambulatory patients.
